Clinical trials: Neoplasms, Oral
Oral Mucositis
Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients
to survey oral mucositis after chemotherapy and Concurrent chemoradiotherapy in Korean cancer patients
- Trial name
- NCT00549952
- Testing
- no intervention study
- Where
- South Korea
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Cancer, Breakthrough Cancer Pain
Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a rapid onset, high intensity and short duration pain episode, which takes place within stable background pain control.
- Trial name
- REBORN (NCT03564548)
- Testing
- PPP001, Morphine sulfate or Hydromorphone or Oxycodone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tetra Bio-Pharma
Carcinoma, Hepatocellular
Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.
- Trial name
- NCT00225290
- Testing
- Thalidomide(Thado)
- Where
- Taiwan
- Volunteers
- 230 people
- Sponsor
- TTY Biopharm
Cancer
Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors
The purpose of this study is to investigate whether ketoconazole, taken orally, influences the level of eribulin in the blood when the two drugs are given at the same time.
- Trial name
- NCT01000376
- Testing
- Eribulin alone, Eribulin plus Ketoconazole
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Eisai Limited
Solid Malignancies
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.
- Trial name
- NCT01112397
- Testing
- AZD1480
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
- Trial name
- NCT02189174
- Testing
- CLR457
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell…
- Trial name
- NCT06525220
- Testing
- Petosemtamab, Pembrolizumab
- Where
- 202 sites in United States, Argentina and 26 more
- Volunteers
- 699 people
- Sponsor
- Genmab
Advanced Hematologic Malignancies
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after…
- Trial name
- NCT07444268
- Testing
- DSP-5336, [14C]-DSP-5336
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sumitomo Pharma America, Inc.
Multiple Myeloma
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
This study comprises of a dose-escalation and dose expansion phase and will determine the maximum tolerated dose of oral Panobinostat on a continuous schedule in adult in combination with bortezomib.
- Trial name
- NCT00532389
- Testing
- LBH589
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Lung Neoplasms
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage…
- Trial name
- NCT00074854
- Testing
- CP-547,632
- Where
- 20 sites in United States
- Volunteers
- 87 people
- Sponsor
- Pfizer
Uterine Fibroids, Heavy Menstrual Bleeding
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids…
- Trial name
- PRIMROSE 2 (NCT03070951)
- Testing
- OBE2109, Add-back
- Where
- 96 sites in United States, Bulgaria and 7 more
- Volunteers
- 511 people
- Sponsor
- ObsEva SA
Medical Oncology
Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
To evaluate the effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of roniciclib in cancer patients. To assess safety and tolerability of roniciclib dosing when administered with and without itraconazole…
- Trial name
- NCT02457351
- Testing
- Roniciclib (BAY 1000394), Itraconazole (Sporanox)
- Where
- 4 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Bayer
Genital Warts, Perianal Warts
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations…
- Trial name
- NCT01082302
- Testing
- Polyphenon E (Veregen) 15% ointment, Green Tea Beverage with defined catechin content
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- MediGene
Ulcerative Colitis
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis
The purpose of this study is to evaluate the safety and tolerability as well as the pharmacodynamic effects of multiple doses of AVX-470 administered orally in patients with active ulcerative colitis.
- Trial name
- NCT01759056
- Testing
- AVX 470
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 33 people
- Sponsor
- Avaxia Biologics, Incorporated
Advanced Solid Tumors (Excluding Breast Cancer)
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
The purpose of this study is to compare the bioavailability of TAS-102 tablets to an oral solution containing equivalent amounts FTD and TPI.
- Trial name
- NCT01874522
- Testing
- TAS-102 tablets, TAS-102 oral solution
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Taiho Oncology, Inc.
Solid Tumours
Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the pharmacokinetics (PK) of AZD9291 in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function…
- Trial name
- NCT02161770
- Testing
- AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Melanoma and Metastatic Colorectal Cancer
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase…
- Trial name
- NCT01436656
- Testing
- LGX818
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 107 people
- Sponsor
- Pfizer
Uterine Leiomyomata (Fibroids)
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females
The primary purpose of this study is to assess the safety and tolerability of ascending single oral doses of PRA-027 in healthy Japanese females.
- Trial name
- NCT00444704
- Testing
- PRA-027
- Where
- Japan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cancer
A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer
The purpose of this study is to determine what effects Esomeprazole (Nexium) has on increasing or decreasing the amount of oral taxane in the blood, and to determine the safety of oral taxane and effect of oral taxane on the…
- Trial name
- NCT00332748
- Testing
- Oral Taxane
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Cholangiocarcinoma
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered…
- Trial name
- FIRST-308 (NCT05948475)
- Testing
- Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
- Where
- 87 sites in United States, Austria and 11 more
- Volunteers
- 200 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.